<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02096510</url>
  </required_header>
  <id_info>
    <org_study_id>2013/1738</org_study_id>
    <nct_id>NCT02096510</nct_id>
  </id_info>
  <brief_title>Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia</brief_title>
  <official_title>Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effects of tablet treatment, circadian and combined
      circadian and ultradian subcutaneous hydrocortisone infusion on steroid metabolism and tissue
      responses to therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The conventional glucocorticoid replacement therapy in primary adrenal insufficiency
      (Addison's disease) and congenital adrenal hyperplasia renders the cortisol levels
      unphysiological, which may cause symptoms and long-term complications. This therapeutical
      approach does not enable to restore physiological circadian and ultradian rhythm of
      glucocorticoids. Current studies conclude that constant or unphysiological administration of
      glucocorticoids leads to abnormal gene transcription and causes sides effect of
      glucocorticoids treatment and long standing complications Glucocorticoid replacement is
      technically feasible by continuous subcutaneous hydrocortisone infusion, which can mimic not
      only the normal diurnal cortisol rhythm, but potentially also the ultradian cadence.

      This is a pilot trial with an open cross-over design of 3 x minimum 2 weeks in 10 patients
      comparing the effects of tablet treatment versus continuous subcutaneous hydrocortisone
      infusion versus ultradian subcutaneous hydrocortisone infusion on serum, salivary, tissue
      hormonal response and glucocorticoid related gene expression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum cortisol -24 hours curve</measure>
    <time_frame>24 hours</time_frame>
    <description>admission to hospital for 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Salivary cortisol - 24 hours curve</measure>
    <time_frame>24 hours</time_frame>
    <description>admission to the hospital for 25 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 h urine cortisol and metabolites</measure>
    <time_frame>24 hours</time_frame>
    <description>urine samples for 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>levels of corticotropic hormone</measure>
    <time_frame>24 hours</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hours curve of tissue cortisol</measure>
    <time_frame>24 hours</time_frame>
    <description>The tissue effect of glucocorticoid replacement - 24 hours curve of tissue cortisol (microdialysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gene expression</measure>
    <time_frame>24 hours</time_frame>
    <description>m RNA expression of genes</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Addison Disease</condition>
  <condition>Adrenal Hyperplasia Congenital</condition>
  <arm_group>
    <arm_group_label>continuous subcutaneous hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>continuous subcutaneous hydrocortisone infusion (CSHI), Solu-Cortef ® 50mg/ml infusate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cortef tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the patient regular treatment by Cortef 5 mg, produced by Nycomed Pharma two times or three times a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ultradian subcutaneous hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ultradian subcutaneous hydrocortisone infusion, Solu-Cortef ® 50mg/ml infusate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solu-Cortef</intervention_name>
    <description>administration by pump for minimum 2 weeks</description>
    <arm_group_label>continuous subcutaneous hydrocortisone</arm_group_label>
    <arm_group_label>cortef tablets</arm_group_label>
    <arm_group_label>ultradian subcutaneous hydrocortisone</arm_group_label>
    <other_name>hydrocortisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cortef</intervention_name>
    <description>tablet treatment 2 ro 3 times per day for 14 days</description>
    <arm_group_label>continuous subcutaneous hydrocortisone</arm_group_label>
    <arm_group_label>cortef tablets</arm_group_label>
    <arm_group_label>ultradian subcutaneous hydrocortisone</arm_group_label>
    <other_name>hydrocortisone tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. clinical diagnosis of primary adrenal insufficiency

          2. Written informed consent

        Exclusion Criteria:.

          1. Diabetes mellitus

          2. Severe cardiovascular disease

          3. Active malignant disease

          4. Pregnancy or breast feeding

          5. treatment with interfering drugs

          6. Intake of grapefruit juice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katerina Simunkova, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universtity of Bergen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristian Løvås, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Helse Bergen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristian Løvås, MD, PhD</last_name>
    <phone>55973075</phone>
    <email>kristian.lovas@helse-bergen.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katerina Simunkova, MD, PhD</last_name>
    <phone>41079948</phone>
    <email>katerina.simunkova@k2.uib.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Helse Bergen</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katerina Simunkova, MD, PhD</last_name>
      <phone>41079948</phone>
      <email>katerina.simunkova@k2.uib.no</email>
    </contact>
    <contact_backup>
      <last_name>Kristian Løvås, MD, PhD</last_name>
      <phone>55973075</phone>
      <email>kristian.lovas@helse-bergen.no</email>
    </contact_backup>
    <investigator>
      <last_name>Kristian Løvås, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katerina Simunkova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Lightman SL, Conway-Campbell BL. The crucial role of pulsatile activity of the HPA axis for continuous dynamic equilibration. Nat Rev Neurosci. 2010 Oct;11(10):710-8. doi: 10.1038/nrn2914. Epub 2010 Sep 15. Review.</citation>
    <PMID>20842176</PMID>
  </reference>
  <reference>
    <citation>Løvås K, Husebye ES. Continuous subcutaneous hydrocortisone infusion in Addison's disease. Eur J Endocrinol. 2007 Jul;157(1):109-12. Erratum in: Eur J Endocrinol. 2008 Jun;158(6):939. Dosage error in article text.</citation>
    <PMID>17609409</PMID>
  </reference>
  <reference>
    <citation>Lightman SL, Windle RJ, Julian MD, Harbuz MS, Shanks N, Wood SA, Kershaw YM, Ingram CD. Significance of pulsatility in the HPA axis. Novartis Found Symp. 2000;227:244-57; discussion 257-60. Review.</citation>
    <PMID>10752074</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2013</study_first_submitted>
  <study_first_submitted_qc>March 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2014</study_first_posted>
  <last_update_submitted>December 20, 2016</last_update_submitted>
  <last_update_submitted_qc>December 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Addison Disease</keyword>
  <keyword>Adrenal Hyperplasia Congenital</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Adrenal Hyperplasia, Congenital</mesh_term>
    <mesh_term>Adrenogenital Syndrome</mesh_term>
    <mesh_term>Adrenocortical Hyperfunction</mesh_term>
    <mesh_term>Addison Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

